7 Hills Pharma announces the expansion of its patent portfolio with new claims covering innovative integrin agonist combination therapies. The newly issued patent no. 11,311,619 strengthens 7HP’s leadership in leveraging integrin activation to overcome immunotherapy resistance, expanding applications across diverse therapeutic areas.

7 Hills Pharma secures broad USPTO patent protection for its integrin activators, positioning the company as a key partner for immuno-oncology and COVID-19 vaccine developers. FDA-approved IND trials set to begin soon.